Protalix BioTherapeutics Inc (PLX)
1.05
-0.02
(-1.87%)
USD |
NYAM |
Sep 27, 16:00
1.055
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics SG&A Expense (Annual): 14.96M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.96M |
| December 31, 2022 | 11.71M |
| December 31, 2021 | 12.73M |
| December 31, 2020 | 11.15M |
| December 31, 2019 | 9.899M |
| December 31, 2018 | 10.92M |
| December 31, 2017 | 11.53M |
| December 31, 2016 | 9.356M |
| December 31, 2015 | 7.279M |
| December 31, 2014 | 9.228M |
| December 31, 2013 | 8.051M |
| December 31, 2012 | 9.763M |
| December 31, 2011 | 6.931M |
| December 31, 2010 | 6.876M |
| Date | Value |
|---|---|
| December 31, 2009 | 7.144M |
| December 31, 2008 | 6.77M |
| December 31, 2007 | 20.59M |
| December 31, 2006 | 4.525M |
| December 31, 2005 | 2.131M |
| December 31, 2004 | 0.807M |
| December 31, 2003 | 0.1474M |
| December 31, 2002 | 0.1658M |
| December 31, 2001 | 0.2918M |
| December 31, 2000 | 0.3819M |
| December 31, 1999 | 1.524M |
| December 31, 1998 | 2.086M |
| December 31, 1997 | 0.1644M |
| December 31, 1996 | 0.0441M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
9.899M
Minimum
2019
14.96M
Maximum
2023
12.09M
Average
11.71M
Median
2022
SG&A Expense (Annual) Benchmarks
| Aethlon Medical Inc | 12.64M |
| Predictive Oncology Inc | 10.94M |
| bluebird bio Inc | 165.51M |
| AIM ImmunoTech Inc | 21.14M |
| Armata Pharmaceuticals Inc | 11.65M |